A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Despite the powerful cancer-fighting capabilities of treatments based on T cells containing an engineered chimeric antigen receptor (CAR) to fight a patient’s cancer, one key challenge is ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now discovered that CAR molecules can be transferred from the CAR-T cells to ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Penn Medicine is advancing cancer treatment with its work in CAR T-cell therapy, an innovative immunotherapy that is reshaping the fight against blood cancers and rare genetic diseases. Penn Medicine ...

Treatment with the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) continued to demonstrate durable responses after a median follow-up of more than five years in patients with ...